GH Peptide Side Effects in the Research: Ipamorelin, CJC-1295, Sermorelin, Tesamorelin
What the published trials actually report on growth-hormone peptide tolerability: injection-site reactions, IGF-1 elevation, fluid balance and glucose, plus the honest limits of the human evidence.
TL;DR: What the trials report
Two mechanistic families get lumped together. GHRH-receptor agonists (Sermorelin, CJC-1295, Tesamorelin) and the ghrelin-receptor agonist Ipamorelin act on different receptors, so their off-target profiles differ. The most consistent class signal is IGF-1 elevation: tesamorelin raised IGF-1 by about 81 percent in its pivotal trial (PMID 18057338), and IGF-1 is the standard monitored biomarker across these studies. Injection-site reactions are the most commonly reported adverse event in the tesamorelin (Egrifta) program. Ipamorelin's distinguishing feature is selectivity: in conscious swine it released GH without the cortisol rise seen with older GHRPs (PMID 9849822). Glucose stayed stable in the controlled tesamorelin trials at studied doses (PMID 18057338, 18690162, 20943777), even though classic GH pharmacology predicts reduced insulin sensitivity, an honest tension worth naming.
Search "GH peptide side effects" and you mostly find forum anecdotes. This article does the opposite: it reports only what the published human and preclinical studies actually measured, compound by compound, with the central empirical claims tied to verifiable PMIDs. It is a research-context explainer for laboratory use, with no dosing, no protocols and no second-person "this will happen to you" framing. Where a study used humans, it was a specific population (HIV patients, GH-deficient children, healthy male volunteers), and that context is stated every time so nothing gets over-generalised.
Growth hormone secretagogues and gonadotropins
Two Families Under One Name
"GH peptides" is a loose label covering two distinct receptor mechanisms:
- GHRH-receptor agonists: Sermorelin (GHRH 1-29), Tesamorelin (a stabilised GHRH analogue) and CJC-1295 (a long-acting GHRH analogue). These act on pituitary somatotroph GHRH receptors to stimulate GH synthesis and release.
- Ghrelin-receptor (GHS-R1a) agonists: Ipamorelin, a GH-releasing peptide acting on a separate receptor.
Because the two families stimulate GH through complementary pathways, combining them is a theoretical complementary-pathway rationale, and the CJC-1295 and Ipamorelin blend exists for that research pairing. It also means their side-effect profiles are not identical, so they deserve to be read separately rather than as one undifferentiated "GH peptide" category.
How Researchers Read GH-Peptide Safety
Across these compounds, a handful of shared endpoints recur in the literature: IGF-1 elevation (the consistent downstream biomarker), injection-site reactions, fluid balance (sodium and water retention is a classic GH effect), and glucose and insulin sensitivity. Classic GH-axis pharmacology predicts that pushing GH and IGF-1 high can cause fluid retention, joint aches (arthralgia) and reduced insulin sensitivity. Naming those theoretical class effects honestly matters, even where a given trial did not surface them, and the sections below separate what was predicted from what was measured.
Ipamorelin: Receptor Selectivity Is the Headline
The selectivity data (PMID 9849822)
Ipamorelin was characterised as the first selective GH secretagogue. In conscious swine it released GH comparably to the older peptides GHRP-6 and GHRP-2, but it did not raise ACTH or cortisol above the level seen with GHRH alone, and it had no effect on FSH, LH, prolactin or TSH. At equimolar GH-stimulating doses, GHRP-6 raised cortisol about 47 percent and GHRP-2 about 31 percent, while ipamorelin produced no statistically significant cortisol change. The selectivity held even at doses more than 200-fold above the ED50 for GH release.
That selectivity, GH release without the cortisol and prolactin activation that characterised earlier GHRPs, is the single cleanest citable point about ipamorelin's tolerability profile. The honest limitation: this evidence is largely preclinical and early-phase, and ipamorelin has no approved human indication, so its human tolerability data are thin compared to the GHRH analogues below.
Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.
CJC-1295: The DAC-versus-no-DAC Distinction
A single subcutaneous dose of CJC-1295 DAC (the drug-affinity-complex, long-acting form) produced dose-dependent 2- to 10-fold increases in mean plasma GH for six or more days and 1.5- to 3-fold increases in IGF-1 for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days and a cumulative effect after repeated dosing; it was reported generally well tolerated in that study, though its small size and short duration in healthy adults restrict any safety inference (PMID 16352683). The mechanistic caveat comes from a second study, in healthy men: during continuous exposure, GH pulse frequency and magnitude were unaltered, but basal (trough) GH rose about 7.5-fold, and it was this raised trough, not a change in pulses, that drove the IGF-1 increase (PMID 17018654).
Do not blur DAC and no-DAC
The multi-day pharmacokinetics, cumulative dosing effect and raised-GH-trough finding are documented for the DAC form specifically. The stocked CJC-1295 (and the blend) is the short-acting no-DAC variant (modified GRF 1-29), which lacks comparable dedicated human trial evidence, so the DAC safety and PK data above do not describe the stocked product. The DAC sustained-exposure profile, days-long continuous elevation that flattens the normal low-trough physiology, is a limitation to report neutrally, not a benefit.
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH(1-29) analog for GH/IGF-1 research. Research-grade lyophilized powder, specified purity >=99% (HPLC). Laboratory use only.
Sermorelin: A Long Diagnostic and Pediatric Safety Record
Sermorelin (GHRH 1-29) has the longest tolerability track record of the four. As a provocative test for GH deficiency it produced fewer false-positive GH responses than other provocative tests, and its adverse effects were uncommon and usually mild, most often transient facial warmth or flushing (typically resolving within about five minutes) and injection-site pain or redness (PMID 18031173). It was FDA-approved for diagnostic use in 1990 and for pediatric idiopathic GH deficiency (as Geref) in 1997. That approval history is background on the molecule's safety record, not an offered use: we do not sell it to treat GH deficiency or anything else.
GHRH(1-29) analog for physiological growth hormone stimulation research
Tesamorelin: The Richest Controlled Human Safety Data
Tesamorelin has the deepest controlled human safety dataset. Its principal phase-3 safety evidence comes from one specific patient population (HIV-associated lipodystrophy), with only limited short-term data in healthy men, and that context is essential.
The Egrifta trials (PMID 18057338, 18690162, 20101189)
In the pivotal phase-3 trial (n=412, HIV-associated lipodystrophy, 26 weeks), tesamorelin reduced visceral adipose tissue about 15.2 percent versus a 5.0 percent increase on placebo, and raised IGF-1 about 81.0 percent versus -5.0 percent on placebo, while no significant difference was seen in glycemic measures over 26 weeks (PMID 18057338). A 52-week safety extension found it generally well tolerated, with adverse-event rates comparable to the initial phase and glucose changes that were not clinically significant (PMID 18690162). A second phase-3 RCT confirmed the same pattern: significant IGF-1 elevation with visceral-fat reduction and no change in glucose parameters (PMID 20101189). Injection-site reactions are the most commonly reported adverse event in the tesamorelin (Egrifta) program.
Approved-drug context, not a body-composition claim
Tesamorelin is FDA-approved in the US (as Egrifta) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and it is not authorised in the EU. Its trials are disease-population research. Extrapolating that data to healthy-adult fat loss, anti-aging or physique goals would convert approved-drug evidence into an off-label human claim, which we do not make. The visceral-fat and IGF-1 figures are trial outcomes in HIV patients, not results a reader should expect.
Modified GHRH analog for lipodystrophy and metabolic liver research
Glucose and Insulin: Prediction Versus Measurement
This is the most interesting tension in the data. Classic GH pharmacology predicts reduced insulin sensitivity when GH and IGF-1 are pushed high, and the oral ghrelin agonist MK-677 did raise fasting glucose and reduce insulin sensitivity over two years (PMID 18981485). Yet in the controlled tesamorelin trials, glucose parameters did not change clinically significantly over 26 and 52 weeks (PMID 18057338, 18690162), and in healthy men, two weeks of a GHRH analogue raised overnight GH and IGF-1 significantly while neither fasting glucose nor insulin-stimulated glucose uptake was significantly affected (PMID 20943777). The honest reading: the theoretical GH-driven insulin-resistance concern is real class pharmacology, but the controlled GHRH-analogue trials at their studied doses did not show it, while the sustained-exposure oral agent did. Agent, exposure pattern, population and study duration all differed, so these studies cannot by themselves identify the reason.
Depth-of-Evidence Scoreboard
The evidence is very uneven
Tesamorelin: richest controlled human safety data (multiple phase-3 RCTs plus a 52-week extension), but only in HIV-lipodystrophy patients (PMID 18057338, 18690162, 20101189). Sermorelin: decades of diagnostic and pediatric safety experience (PMID 18031173). CJC-1295: limited early-phase human data, and only for the DAC form (PMID 16352683, 17018654). Ipamorelin: selectivity evidence is largely preclinical and early, with no approved human indication (PMID 9849822). None of these is offered as a treatment, and much of the strongest data comes from populations (HIV patients, GH-deficient children, healthy male volunteers) and durations that do not generalise to arbitrary use.
Selective ghrelin-receptor research
GHRH-analogue research (stocked form is short-acting no-DAC)
Stocked Research Peptides and Handling
Ipamorelin, CJC-1295, Sermorelin, Tesamorelin and the CJC-1295 and Ipamorelin blend are supplied for laboratory research only and are not intended for human consumption. The stocked CJC-1295 and blend are the short-acting no-DAC (modified GRF 1-29) form, not the long-acting DAC form whose multi-day data appear above. This article gives no dosing, titration or reconstitution-for-use instructions; the trial doses mentioned are study parameters inside their cited context, not a suggested regimen. Check the supplier-provided, batch-specific third-party Certificate of Analysis for the tested batch, and see the growth hormone peptides overview, the MK-677 versus Ipamorelin and CJC-1295 comparison and the IGF-1 biomarker explainer for the wider picture.
Frequently Asked Questions
This article is for research and educational purposes only. It reports side effects and outcomes as measured in the cited studies and their specific populations, not as results a reader should expect. Tesamorelin and sermorelin approval histories are described as regulatory background, not offered uses. Nothing here is medical advice, a health claim, dosing guidance or a recommendation for use. All compounds mentioned are sold exclusively for laboratory research.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.